-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, I1n8C6XSoAqhcEJs/Vn2IKgdk9s7hfaX169KPHEtIIA3Gxgvs1h4sIhO6rB725Sj UV4VFCv0SEXjyDAuuejkdA== 0001179110-05-007318.txt : 20050405 0001179110-05-007318.hdr.sgml : 20050405 20050405171816 ACCESSION NUMBER: 0001179110-05-007318 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20050111 FILED AS OF DATE: 20050405 DATE AS OF CHANGE: 20050405 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MANHATTAN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001001316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 363898269 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 787 SEVENTH AVENUE STREET 2: 48TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: 2125544555 MAIL ADDRESS: STREET 1: 787 SEVENTH AVENUE STREET 2: 48TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC TECHNOLOGY VENTURES INC DATE OF NAME CHANGE: 20000330 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19960703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: WEISER MICHAEL CENTRAL INDEX KEY: 0001221449 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-27282 FILM NUMBER: 05734941 MAIL ADDRESS: STREET 1: 130 EAST 75TH ST STREET 2: APT 6B CITY: NEW YORK STATE: NY ZIP: 10021 4 1 edgar.xml FORM 4 - X0202 4 2005-01-11 0 0001001316 MANHATTAN PHARMACEUTICALS INC MHTT 0001221449 WEISER MICHAEL 787 SEVENTH AVENUE, 48TH FLOOR NEW YORK NY 10019 1 0 0 0 Common Stock 2005-04-01 4 A 0 851778 A 2208338 D Warrant 1.21 2004-01-27 2009-01-27 Common Stock 103655 103655 D Option 1.65 2014-01-27 Common Stock 75000 75000 D Director Stock Option 1 2005-01-11 4 A 0 30000 0 A 2015-01-11 Commn Stock 30000 30000 D Received in exchange for 317,500 shares of Tarpan Therapeutics, Inc., a privately-held company, in connection with the merger of Tarpan into Manhattan Pharmaceuticals, Inc. (the "Merger"). On the effective date of the Merger, the closing price of Manhattan's common stock was $1.50. The shares of Manhattan common stock issued in the Merger are believed to be fair consideration for the Tarpan shares. 50,000 shares have vested. 25,000 shares vest, if at all, on 1/28/06. Under the 2003 Stock Option Plan 10,000 shares vest on each of 1/11/05, 1/11/06, and 1/11/07. /s/ Michael Weiser 2005-04-05 -----END PRIVACY-ENHANCED MESSAGE-----